Publications & Posters

Poster

OPN-9840, a non-covalent potent pan-TEAD inhibitor, exhibits single agent efficacy in preclinical malignant mesothelioma models

Download PDF
Poster

OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC

  • AUTHORS Matusow, et al
  • Programs OPN-6602
Download PDF
Poster

OPN-6602, a dual EP300/CBP bromodomain inhibitor modulates androgen-driven transcription in mCRPC

  • AUTHORS Matusow, et al
  • Programs OPN-6602
Download PDF
Publication

Phase IIa Study of PLX2853 in Gynecologic Cancers with known ARID1A mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-resistant epithelial ovarian cancer

  • AUTHORS Duska, et al
  • Programs OPN-2853
https://ascopubs.org/doi/abs/10.1200/PO.23.00235
Poster

Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cancer

  • AUTHORS Swisher, et al
  • Programs OPN-2853
Download PDF
Publication

Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine

https://doi.org/10.1016/j.leukres.2022.106884
Publication

Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft- Versus-Host Disease

https://doi.org/10.3389/fonc.2021.760789
Poster

Phase 1b/2a Study of PLX2853, a Small Molecule BET Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma

  • AUTHORS Gordon, et al
  • Programs OPN-2853
Download PDF
Publication

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia

https://doi.org/10.3324/haematol.2020.247346
Poster

Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Download PDF